<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352039</url>
  </required_header>
  <id_info>
    <org_study_id>EF098 - HEP-SC</org_study_id>
    <nct_id>NCT01352039</nct_id>
  </id_info>
  <brief_title>A Non-inferiority Study Comparing Two Heparin Sodium Preparations in Hip Fracture Surgery</brief_title>
  <acronym>HEP-SC</acronym>
  <official_title>A Phase III, Non-inferiority, Randomized, Double-blind Trial Comparing Eurofarma Unfractionated Sodium Heparin 5,000 IU to APP Pharmaceuticals Unfractionated Sodium Heparin 5,000 IU in the Thromboprophylaxis of Geriatric Patients Who Underwent Hip Fracture Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective and endpoints of the study is compare the efficacy of two products
      containing heparin sodium, evaluating if the formulation produced by Eurofarma can be
      considered non-inferior to the reference product.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to assess the efficacy of unfractionated heparin sodium
      of porcine origin (Eurofarma) in the prophylaxis of VTE relative to unfractionated heparin
      sodium of porcine origin from APP Pharmaceuticals. The primary endpoint will be the frequency
      of DVT determined by Doppler ultrasound (DUS).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary endpoint will be frequency of deep venous thrombosis (DVT) determined by Doppler ultrasound (DUS).</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Secundary endpoint will be proximal and distal DVT</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">544</enrollment>
  <condition>Hip Fracture Surgery</condition>
  <arm_group>
    <arm_group_label>Heparin Sodium - Eurofarma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin Sodium - APP Pharmaceuticals</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Heparin Sodium - Eurofarma</intervention_name>
    <description>Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI</description>
    <arm_group_label>Heparin Sodium - Eurofarma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Heparin Sodium - APP Pharmaceuticals</intervention_name>
    <description>Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI</description>
    <arm_group_label>Heparin Sodium - APP Pharmaceuticals</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In order to be enrolled in this study, eligible patients must meet all criteria below:

          -  ICF signing;

          -  Aged 60 to 85 years old;

          -  Indication of hip orthopedic surgery due to fracture occurred within the last 5 days;

          -  Normal coagulation profile or with alterations up to 25% of normal values.

        Exclusion Criteria:

        Patients who meet any of the following criteria will not be eligible for the study:

          -  Previous hip surgery;

          -  Fracture secondary to the presence of metastasis;

          -  Recent traumatic brain, thoracic, or abdominal injury (up to 30 days before study
             start);

          -  Recent occurrence (up to 30 days before study start) of cerebrovascular accident;

          -  Serum concentration of hemoglobin below 9 g/dL;

          -  Prior occurrence (in the last 5 years) of confirmed or suspected thromboembolic event;

          -  Occurrence of major bleeding in the last 6 months (any spontaneous gastrointestinal
             bleeding; central nervous system bleeding; massive epistaxis, or gum bleeding; gross
             hematuria, or vaginal bleeding);

          -  Confirmed or suspected blood dyscrasia;

          -  Diagnosis of neoplasm other than in situ in the last 24 months or any active neoplasm
             (neoplasms in situ do not prevent patient from participating);

          -  Liver or kidney failure;

          -  Clinically significant gastrointestinal cardiovascular, neurological disease, or
             laboratory abnormalities, which at the investigator's opinion, may interfere with
             individual's participation in the study or with assessment of individual's response to
             treatment;

          -  Hypersensitivity to heparin;

          -  Previous use (15 days before study start) of oral anticoagulants or expected use
             during the study (see Appendix B);

          -  Recent participation (previous 12 months) in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia de Belo Horizonte</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica da Santa Casa de Misericórida de Juíz de Fora</name>
      <address>
        <city>Juiz de Fora</city>
        <state>Minas Gerais</state>
        <zip>36021-630</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associação Hospitalar Moinhos de Vento</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade Santa Casa de Misericórdia de Marília</name>
      <address>
        <city>Marília</city>
        <state>São Paulo</state>
        <zip>17515-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2011</study_first_submitted>
  <study_first_submitted_qc>May 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2011</study_first_posted>
  <last_update_submitted>October 15, 2012</last_update_submitted>
  <last_update_submitted_qc>October 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heparin Sodium</keyword>
  <keyword>Thromboprophylaxis</keyword>
  <keyword>Hip Fracture Surgery.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

